Last reviewed · How we verify

NCT07462351: SPRING

System-integrated Point-of-Care Ultrasound in Breast Cancer Screening

Recruiting now NA Last updated 13 April 2026
What this trial tests

NA trial testing AI in Breast Cancer in 4,800 participants. Currently enrolling.

Timeline
11 March 2026
Primary endpoint
23 May 2026
31 December 2026

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment4,800
Start date11 March 2026
Primary completion23 May 2026
Estimated completion31 December 2026
Sites1 location across Ethiopia

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the feasibility, safety, and clinical performance of community-based breast cancer screening incorporating clinical breast exam and short-termed trained examiners performing AI-supported breast POCUS for triage in limited-resource settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of AI

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07462351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing